LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.
| LumiraDx Second Quarter 2022 Financial Results Conference Call | |
| Date: | Thursday, August 18, 2022 |
| Time: | 8:00 AM Eastern Time |
| Live Call/Webcast: | Register to join by phone here. https://investors.lumiradx.com/news-and-events/investor-calendar |
A replay of the webcast will be available on the Investor’s section of the company’s website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.
About LumiraDx
LumiraDx (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
Further information on LumiraDx and the LumiraDx Platform is available at www.lumiradx.com
Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75%…
Digital health platform offers FDA-approved treatments when appropriate and personalized care plans through licensed providers.New…
NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem RALEIGH, N.C., June…
MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…
New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…
TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
